A daily, switch-hitting plan. In uptrends it either buys biotech dips or the 3 strongest mega‑caps, but hedges with UVXY or SQQQ when things look overheated/whipsaw. In downtrends it favors UVXY/SQQQ/bonds, touching LABU only on deep oversold.

Daily check: if SPY is above its 200‑day average, it’s risk‑on. Then it: a) buys UVXY when markets look overheated; b) after sharp Nasdaq drops, may short tech (SQQQ); c) else buys biotech on deep dips (LABU) or the 3 best‑performing mega‑caps (last 20 days). If SPY is below the 200‑day, it’s risk‑off and it rotates among UVXY, SQQQ, short‑term bonds (BSV), or LABU when selling looks washed‑out.

Out-of-sample edge: ~31.2% annualized return vs S&P ~20.2%, with Calmar ~0.89 and Sharpe ~0.79. A regime-switching biotech/mega-cap momentum strategy using volatility hedges aims for outsized upside while actively managing downside.